These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19265601)

  • 21. Management of HIV: a swing back to the future.
    Alozie OK; Bonham S; Henry WK
    Minn Med; 2009 Oct; 92(10):45-9. PubMed ID: 19916274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug interactions chart. An abbreviated, at-a-glance guide to HIV drug interactions.
    Diaz-Linares M; Vázquez E
    Posit Aware; 2008; 19(1):50-2. PubMed ID: 18546578
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug interactions chart. An abbreviated, at-a-glance guide to HIV drug interactions.
    Djuricich P; Vázquez E
    Posit Aware; 2009; 20(2):56-8. PubMed ID: 19280746
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9 years in Taiwan.
    Tseng SH; Jiang DD; Hoi HS; Yang SL; Hwang KP
    Am J Trop Med Hyg; 2009 Apr; 80(4):675-7. PubMed ID: 19346398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvements in antiretroviral therapy outcomes over calendar time.
    Boyd MA
    Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Szczech LA
    Curr Opin HIV AIDS; 2009 May; 4(3):167-70. PubMed ID: 19532045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Full viral suppression newest trend seen in the "post-HAART" era. New immunotherapy treatment could help with trend.
    AIDS Alert; 2008 Mar; 23(3):25-7. PubMed ID: 18661635
    [No Abstract]   [Full Text] [Related]  

  • 29. Predicting the potential benefits of early initiation of ART: time to do a trial to find out.
    Phillips AN; Emery S
    Curr Opin HIV AIDS; 2009 May; 4(3):165-6. PubMed ID: 19532044
    [No Abstract]   [Full Text] [Related]  

  • 30. Myelodysplastic syndrome with complex karyotype associated with long-term highly active antiretroviral therapy.
    Rieg S; Lübbert M; Kern WV; Timme S; Gärtner F; Rump JA
    Br J Haematol; 2009 Jun; 145(5):670-3. PubMed ID: 19344389
    [No Abstract]   [Full Text] [Related]  

  • 31. Sustaining treatment costs: who will pay?
    Zewdie D; De Cock K; Piot P
    AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744
    [No Abstract]   [Full Text] [Related]  

  • 32. Update from CROI 2008 on approved HIV drugs.
    Dalton P
    Proj Inf Perspect; 2008 Apr; (45):9-17. PubMed ID: 19248293
    [No Abstract]   [Full Text] [Related]  

  • 33. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 34. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early initiation of ART produces better clinical outcomes.
    Clin Infect Dis; 2009 Apr; 48(8):iii. PubMed ID: 19301458
    [No Abstract]   [Full Text] [Related]  

  • 36. Social aspects of antiretroviral therapy scale-up: introduction and overview.
    Hirsch JS; Parker RG; Aggleton P
    AIDS; 2007 Oct; 21 Suppl 5():S1-4. PubMed ID: 18090262
    [No Abstract]   [Full Text] [Related]  

  • 37. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Chang SY; Lin SW; Hung CC
    Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
    [No Abstract]   [Full Text] [Related]  

  • 38. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective].
    Wepner U
    MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085
    [No Abstract]   [Full Text] [Related]  

  • 39. Update from CROI 2008 on HIV-related infections and conditions.
    McCord A
    Proj Inf Perspect; 2008 Apr; (45):17-24. PubMed ID: 19248294
    [No Abstract]   [Full Text] [Related]  

  • 40. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
    J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.